Evidence map›Paper›PMID 32611374›Full record

Trial reportBMC research notes2020

Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts.

Kalle Savolainen, Mauro Scaravilli, Antti Ilvesmäki, Synnöve Staff, Teemu Tolonen, Johanna U Mäenpää, Tapio Visakorpi, Annika Auranen

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC research notes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02758652 (Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer), which is not on this map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02758652 unknown statusnot on this map

Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer

TypeobservationalSponsorTampere University HospitalRan2016 to 2026Enrolled160ConditionsOvarian Cancer
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kalle SavolainenDepartment of Obstetrics and Gynecology, Tampere University Hospital, P.O.box 2000, 33521, Tampere, Finland. kalle.savolainen@fimnet.fi.ORCID http://orcid.org/0000-0002-1244-7200
Mauro ScaravilliTays Cancer Centre, Tampere University Hospital and Tampere University, Tampere, Finland.
Antti IlvesmäkiDepartment of Obstetrics and Gynecology, Tampere University Hospital, P.O.box 2000, 33521, Tampere, Finland.
Synnöve StaffDepartment of Obstetrics and Gynecology, Tampere University Hospital, P.O.box 2000, 33521, Tampere, Finland.
Teemu TolonenTays Cancer Centre, Tampere University Hospital and Tampere University, Tampere, Finland.
Johanna U MäenpääDepartment of Obstetrics and Gynecology, Tampere University Hospital, P.O.box 2000, 33521, Tampere, Finland.
Tapio VisakorpiTays Cancer Centre, Tampere University Hospital and Tampere University, Tampere, Finland.
Annika AuranenDepartment of Obstetrics and Gynecology, Tampere University Hospital, P.O.box 2000, 33521, Tampere, Finland.
Tampere University · FITampere University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePlasma, but also urine sample could represent a simple liquid biopsy for ovarian cancer biomarker detection. The miRNA-200 family has been shown to be dysregulated in ovarian cancer. The aim of this study was to isolate three members of miR-200 family from tumor tissue, plasma and urine of high-grade serous ovarian cancer patients in comparison with samples from patients with benign ovarian tumors. This is a methodological pilot study of a prospective ovarian cancer patient cohort investigating the potential of liquid biopsies and the role of miRNAs in ovarian cancer treatment.

resultsMiR-200a, miR-200b and miR-200c were isolated from samples of nine ovarian cancer patients and seven patients with benign ovarian tumor. The most significant finding is that all three miRNAs were detectable in all sample types. Tumor tissue and plasma, but not urine analysis was able to discriminate malignant and benign samples. A correlation between the miRNA-200 expression in urine and plasma was observed in malignant samples only. Plasma and urine with respect to miRNA detection show potential according to this study, but larger studies are needed to clarify the usefulness of these liquid biopsies in ovarian cancer.

trial registrationClinicalTrials.gov NCT02758652, May 2, 2016.

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, Ovarian EpithelialCohort StudiesFemaleHumansMicroRNAsMiddle AgedOvarian NeoplasmsPilot ProjectsBiomarkers, TumorMicroRNAsMIRN200 microRNA, humanMIRN202 microRNA, humanBiomarkerHGSOCLiquid biopsymicroRNAOvarian cancer

Identifiers

PMID32611374
PMCPMC7329467
OpenAlexW3040537235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.